Oxgene Overview
- Founded
- 2011

- Status
- Acquired/Merged
- Employees
- 94

- Latest Deal Type
- M&A
Oxgene General Information
Description
Developer biology-based technologies designed to aid in the discovery and development of biologics, cell, and gene therapies. The company's technologies specialize in DNA design, protein expression optimization, and cell line development technologies along with cloning platform and access to a library of matched plasmid inserts, enabling the bio-therapeutic industry to improve the overall efficiency through the application of synthetic biology.
Contact Information
(Operating Subsidiary)
- Medawar Centre
- Robert Robinson Avenue
- Oxford OX4 4GA
- England, United Kingdom
Oxgene Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
13. Merger/Acquisition | 03-Mar-2021 | 000.00 | Completed | Generating Revenue | ||
12. Later Stage VC | 06-May-2020 | 00.000 | 000.00 | Completed | Generating Revenue | |
11. Later Stage VC | 28-Mar-2019 | 00.000 | 000.00 | 000.00 | Completed | Generating Revenue |
10. Later Stage VC | 21-Aug-2017 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
9. Grant | 14-Feb-2017 | 00.000 | 00.000 | Completed | Generating Revenue | |
8. Early Stage VC | 27-Oct-2016 | 00.000 | 00.000 | 00.000 | Completed | Generating Revenue |
7. Early Stage VC | 17-Mar-2016 | 00.000 | 00.000 | 00.000 | Completed | Generating Revenue |
6. Early Stage VC | 01-Dec-2015 | 00000 | 00.000 | 00.000 | Completed | Startup |
5. Early Stage VC | 09-Jun-2015 | $232K | $965K | 00.000 | Completed | Startup |
4. Early Stage VC | 24-Dec-2014 | $313K | $733K | 00.000 | Completed | Startup |
Oxgene Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
C Ordinary | 00,000 | 00.000000 | 0000.0 | 0000.0 | 00 | 0000.0 | 00.000 | |
C Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
C Ordinary | 00,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
B Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
B Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
A Ordinary | 0,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.00 | |
A Ordinary | 0,000 | 00.000000 | 000.0 | 000.0 | 00 | 000.0 | 0.000 | |
A Ordinary | 0,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
A Ordinary | 1,813 | $0.013184 | $58.17 | $58.17 | 1x | $58.17 | 1.9% | |
A Ordinary | 3,400 | $0.013184 | $58.17 | $58.17 | 1x | $58.17 | 3.57% |
Oxgene Comparisons
Industry
0000000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialOxgene Competitors (26)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Bioline Reagents | Formerly Accelerator/Incubator backed | London, United Kingdom | 00 | 000000&0 | ||
00000000 | Corporation | Alameda, CA | 00 | 000000000 - | ||
0000 000000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 00000000 | 00000 |
000000000 00000000 | Formerly VC-backed | Billerica, MA | 00 | 00000 | 000000&0 | 00000 |
0000000 000000000 | Formerly VC-backed | Tianjin, China | 0000 | 00000 | 00000000000 | 00000 |
Oxgene Patents
Oxgene Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-2592751-A | Process for making adenoassociated viral vectors | Pending | 04-Feb-2020 | 0000000000 | 0 |
GB-2592752-A | Dna amplification method | Pending | 04-Feb-2020 | 00000000 | 0 |
AU-2020235455-A1 | Method of selecting for antibodies | Pending | 08-Mar-2019 | 00000000000 | |
GB-2595404-A | Inducible aav system comprising cumate operator sequences | Pending | 05-Feb-2019 | 000000000 | 0 |
JP-2021502799-A | Retrovirus vector | Pending | 19-Sep-2017 | C12N15/86 |
Oxgene Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialOxgene Former Investors (5)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Canaccord Genuity | Investment Bank | Minority | 000 0000 | 000000 0 | |
Innovate UK | Government | 000 0000 | 000000 0 | ||
Invesco | Asset Manager | Minority | 000 0000 | 000000 0 | |
Invesco Perpetual | Asset Manager | Minority | 000 0000 | 000000 0 | |
Mercia Asset Management | Venture Capital | Minority | 000 0000 | 000000 0 |